Epacadostat and Olaparib Synergistically Inhibit the Growth of BRCA-Proficient Triple-Negative Breast Cancer by Suppressing the Expression of BRCA1 and RAD51
Molecules · 20.03.2026 · 31 (6) · 1039
DOI: 10.3390/molecules31061039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 20.03.2026. Verfasst von Lei Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Medicinal Chemistry, Jiangsu Medical College, Yancheng 224005, China. Hauptthemen laut MEDLINE: Piperazines, Phthalazines, Triple Negative Breast Neoplasms, BRCA1 Protein. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Science and Technology Project of Yancheng, the Jiangsu Medical College Innovative Research Team for Science and Technology, the Natural Science Foundation of the Jiangsu Higher Education Institutions of China.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) cells with intact homologous recombination (HR) repair mechanism can survive treatment with Olaparib, which further limits the clinical application of PARP1/2 inhibitors. Previous studies have demonstrated that inhibition of indoleamine 2,3-dioxygenase (IDO) can enhance the sensitivity of human tumor cells to PARP1/2 inhibitors. However, the mechanisms underlying their synergistic effects in the treatment of TNBC remain unclear. Herein, we demonstrate that the combination of Olaparib and Epacadostat significantly reduces the proliferation of BRCA-proficient MDA-MB-231 and MDA-MB-468 cells compared to either monotherapy. Mechanistically, Epacadostat reduces intracellular kynurenine and NAD+ levels, thereby sensitizing TNBCs to PARP1/2 inhibition and significantly amplifying Olaparib-induced DNA damage. Furthermore, Epacadostat and Olaparib synergistically increase cellular reactive oxygen species (ROS), leading to DNA oxidative damage and apoptosis. In vivo, Epacadostat and Olaparib significantly suppressed MDA-MB-468 tumor growth compared to the monotherapy groups, while promoting an increase in phosphorylated H2AX. Notably, the dual inhibition of IDO1 and PARP1/2 specifically reduced the expression of HR core genes and proteins, such as BRCA1 and RAD51, which may contribute to impaired DNA-damage repair and increased sensitivity to Olaparib. In summary, targeting both IDO1 and PARP1/2 represents a promising combination therapy for BRCA-proficient TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Medicinal Chemistry, Jiangsu Medical College, Yancheng 224005, China.
- Department of Preventive Medicine, Jiangsu Medical College, Yancheng 224005, China.
- Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China.
Förderung
- the Science and Technology Project of Yancheng
- the Jiangsu Medical College Innovative Research Team for Science and Technology
- the Natural Science Foundation of the Jiangsu Higher Education Institutions of China
- Science and Technology Project of Yancheng
- Natural Science Foundation of the Jiangsu Higher Education Institutions of China
- Jiangsu Medical College Innovative Research Team for Science and Technology
Zitieren
APA
Huang, L., Yang, Y., Duan, D., Dai, L., Zhai, B., & Qian, B. (2026). Epacadostat and Olaparib Synergistically Inhibit the Growth of BRCA-Proficient Triple-Negative Breast Cancer by Suppressing the Expression of BRCA1 and RAD51. Molecules, 31(6), 1039. https://doi.org/10.3390/molecules31061039
Vancouver
Huang L, Yang Y, Duan D, Dai L, Zhai B, Qian B. Epacadostat and Olaparib Synergistically Inhibit the Growth of BRCA-Proficient Triple-Negative Breast Cancer by Suppressing the Expression of BRCA1 and RAD51. Molecules. 2026;31(6):1039. doi:10.3390/molecules31061039
BibTeX
@article{Huang2026,
author = {Huang, Lei and Yang, Ye and Duan, Dongxia and Dai, Li and Zhai, Bingxin and Qian, Bingjun},
title = {Epacadostat and Olaparib Synergistically Inhibit the Growth of BRCA-Proficient Triple-Negative Breast Cancer by Suppressing the Expression of BRCA1 and RAD51},
journal = {Molecules},
year = {2026},
volume = {31},
number = {6},
pages = {1039},
doi = {10.3390/molecules31061039}
}
EUVIMED